On April 14, 2016 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that the company and its scientific collaborators will present two studies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, April 16-20, in New Orleans, La (Press release, Myriad Genetics, APR 14, 2016, View Source [SID:1234510815]). The data will highlight early clinical trials of PARP inhibitors targeting the DNA repair pathway and the use of novel biomarkers to select patients for treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Myriad is a leader in developing companion diagnostics for promising new medicines like the PARP inhibitors currently in clinical development," said Richard Wenstrup, M.D., chief medical officer, Myriad Genetics. "Our successful collaborations demonstrate our collective goal of improving patient care through precision medicine. Our growing portfolio of companion diagnostics will achieve that objective by helping physicians select the right treatments for their patients with cancer."

The studies to be presented are described below, and the abstracts are now available at: View Source Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.

Featured AACR (Free AACR Whitepaper) Mini-Symposia

Title: Safety and efficacy results from a Phase 1 dose-escalation trial of the PARP inhibitor talazoparib (BMN-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies.
Date: Sunday, April 17, 2016: 4:30—4:45 p.m. CDT.
Location: Podium CT011.
Presenter: Zev A. Wainberg, M.D., UCLA Medical Center

Title: Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone in combination in a panel of 25 triple-negative breast cancer PDX models: relevance of BRCA mutations, HRD status and other biomarkers.
Date: Tuesday, April 19, 2016: 3:20—3:35 p.m. CDT.
Location: Podium 4353.
Presenter: Olivier Deas, Ph.D., XenTech SAS.